Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 15, 2023

BUY
$138.78 - $176.51 $710,969 - $904,260
5,123 New
5,123 $814,000
Q1 2022

May 16, 2022

SELL
$161.19 - $257.96 $258,871 - $414,283
-1,606 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$247.59 - $304.47 $397,629 - $488,978
1,606 New
1,606 $425,000
Q2 2021

Aug 16, 2021

SELL
$165.87 - $220.95 $789,375 - $1.05 Million
-4,759 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$180.37 - $226.26 $372,103 - $466,774
-2,063 Reduced 30.24%
4,759 $925,000
Q4 2020

Feb 16, 2021

BUY
$148.08 - $206.57 $1.01 Million - $1.41 Million
6,822 New
6,822 $1.31 Million
Q2 2020

Aug 14, 2020

SELL
$94.33 - $140.48 $665,120 - $990,524
-7,051 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$84.96 - $109.14 $599,052 - $769,546
7,051 New
7,051 $681,000
Q2 2019

Aug 14, 2019

SELL
$54.2 - $85.95 $2.48 Million - $3.93 Million
-45,742 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$49.45 - $62.8 $1.18 Million - $1.49 Million
23,798 Added 108.45%
45,742 $2.7 Million
Q4 2018

Feb 14, 2019

BUY
$48.26 - $68.88 $1.06 Million - $1.51 Million
21,944 New
21,944 $1.16 Million

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $6.92B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.